In the wake of the increase in Current Liabilities in the second quarter 2023, Quick Ratio fell to 1.35 below Biocept Inc average.

Within Medical Laboratories industry 30 other companies have achieved higher Quick Ratio than Biocept Inc in second quarter 2023. While Quick Ratio total ranking in the second quarter 2023 has deteriorated compared to the prior quarter from 1628 to 1772.

Explain Quick Ratio?
How much Cash & cash equivalents BIOC�s has?
What are BIOC�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

BIOC Quick Ratio	(Jun 30 2023) Q2	(Mar 31 2023) Q1	(Dec 31 2022) Q4	(Sep 30 2022) Q3	(Jun 30 2022) Q2
Y / Y Current Liabilities Change	-49.01 %	-68.84 %	-53.23 %	-26.48 %	18.43 %
Y / Y Cash & cash equivalent Change	-71.07 %	-75.43 %	-55.32 %	-34.94 %	17.87 %
Quick Ratio MRQ	1.35	1.54	2.34	2.52	2.39
BIOC's Total Ranking	# 1772	# 1628	# 1332	# 1253	# 1253
Seq. Current Liabilities Change	11.61 %	-20.23 %	-22.97 %	-25.64 %	-31.8 %
Seq. Cash & cash equivalent Change	-2.08 %	-47.48 %	-28.43 %	-21.4 %	-16.83 %

Quick Ratio second quarter 2023 Company Ranking
Within:	No.
Medical Laboratories Industry	# 31
Healthcare Sector	# 735
Overall Market	# 1772

Quick Ratio Statistics
High	Average	Low
9.84	2.63	0.13
(Jun 30 2014)		(Sep 30 2016)

Financial Statements
Biocept Inc 's Current Liabilities	$ 5 Millions	Visit BIOC's Balance sheet
Biocept Inc 's Cash & cash equivalent	$ 7 Millions	Visit BIOC's Balance sheet
Source of BIOC's Sales		Visit BIOC's Sales by Geography

Cumulative Biocept Inc 's Quick Ratio

BIOC's Quick Ratio for the trailling 12 Months

BIOC Quick Ratio	(Jun 30 2023) 12 Months	(Mar 31 2023) 12 Months	(Dec 31 2022) 12 Months	(Sep 30 2022) 12 Months	(Jun 30 2022) 12 Months
Y / Y Current Liabilities TTM Growth	-51.45 %	-39.01 %	-9.87 %	3.81 %	9.04 %
Y / Y Cash & cash equivalent TTM Growth	-58.6 %	-41.47 %	-9.75 %	28.61 %	65.02 %
Quick Ratio TTM	2.02	2.27	2.24	2.28	2.37
Total Ranking TTM	# 4398	# 3803	# 3975	# 1144	# 4001
Seq. Current Liabilities TTM Growth	-17.67 %	-26.69 %	-14.7 %	-5.7 %	3.42 %
Seq. Cash & cash equivalent TTM Growth	-26.88 %	-25.54 %	-16.4 %	-9.04 %	3.36 %

Quick ratio ranking by company, industry and sector >> Back to BIOC Financial Strength Comparisons >> Go to Compare BIOC Quick Ratio to its Competitors

On the trailing twelve months basis In spite of the year on year decrease in BIOC's Current Liabilities to $4.90 millions, cumulative Quick Ratio to 2.02 below the BIOC average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Medical Laboratories industry 53 other companies have achieved higher Quick Ratio than Biocept Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2023 from 3803 to 4398.

Explain Quick Ratio?
How much Cash & cash equivalents BIOC�s has?
What are BIOC�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Medical Laboratories Industry	# 54
Healthcare Sector	# 1139
Within the Market	# 4398

trailing twelve months Quick Ratio Statistics
High	Average	Low
7.5	2.49	0.79
(Mar 31 2015)		(Dec 31 2016)

Companies with similar Quick Ratio in the quarter ending Jun 30 2023, within Medical Laboratories Industry	Quick Ratio	Jun 30 2023 MRQ Cash & cash equivalent	Jun 30 2023 MRQ Current Liabilities
Incyte Corporation	3.07	$ 3,423.366 Millions	$ 1,115.607 Millions
Ispecimen inc	2.99	$ 8.242 Millions	$ 2.752 Millions
Absci Corp	2.81	$ 61.048 Millions	$ 21.709 Millions
Burning Rock Biotech Limited	2.43	$ 86.634 Millions	$ 35.710 Millions
Invitae Corporation	2.14	$ 325.137 Millions	$ 151.968 Millions
American Shared Hospital Services	2.04	$ 13.794 Millions	$ 6.756 Millions
Exact Sciences Corporation	1.69	$ 775.712 Millions	$ 458.185 Millions
Renalytix Plc	1.53	$ 24.700 Millions	$ 16.136 Millions
Natera Inc	1.46	$ 354.828 Millions	$ 242.518 Millions
Biocept Inc	1.35	$ 6.633 Millions	$ 4.902 Millions
Radnet Inc	0.95	$ 413.260 Millions	$ 434.234 Millions
Bionexus Gene Lab Corp	0.95	$ 1.759 Millions	$ 1.860 Millions
Fulgent Genetics Inc	0.90	$ 58.348 Millions	$ 64.819 Millions
Labcorp Holdings Inc	0.88	$ 1,930.600 Millions	$ 2,183.300 Millions
Nrc Health	0.67	$ 22.496 Millions	$ 33.736 Millions
Biodesix Inc	0.62	$ 17.409 Millions	$ 27.951 Millions
Psychemedics Corporation	0.53	$ 2.445 Millions	$ 4.572 Millions
Centogene N v	0.44	$ 21.391 Millions	$ 48.570 Millions
Aclarion Inc	0.43	$ 0.605 Millions	$ 1.412 Millions
Inotiv Inc	0.37	$ 22.220 Millions	$ 60.030 Millions
Iqvia Holdings Inc	0.32	$ 1,492.000 Millions	$ 4,699.000 Millions

Date modified: 2026-09-08T15:11:02+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.